The update discloses improvements regarding the progress of the upcoming gameplays of Land and Battles V2 as well as the growth of the community in general.

The post Axie Infinity Releases Development Update for January 2022 appeared first on BitPinas.

TOKYO, Jan 17, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.

At this symposium, the results of a primary analysis of a prospective clinical study evaluating transcatheter arterial chemoembolization (TACE) therapy in combination strategy with lenvatinib (TACTICS-L) in patients with unresectable hepatocellular carcinoma (uHCC) in Japan (Abstract No: 417), as well as research updates on the Phase IV Study (STELLAR) to evaluate safety and tolerability of lenvatinib in patients with advanced/unresectable hepatocellular carcinoma (Abstract No: TPS485) and results from a clinical study to evaluate the efficacy of lenvatinib for conversion surgery in patients with uHCC (investigator-initiated study in Japan, Abstract No: 458), will be presented.

In addition, trial-in-progress (TiP) posters from the clinical program evaluating the combination therapy of lenvatinib plus pembrolizumab (product name: KEYTRUDA), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), include the Phase III LEAP-014 Study of the combination plus chemotherapy in patients with esophageal carcinoma squamous cell carcinoma (Abstract No: TPS367), Phase III LEAP-015 Study of the combination plus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma (Abstract No: TPS369), Phase III Study LEAP-012 of the combination plus TACE in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment (Abstract No: TPS494), and Phase II Study of the combination plus belzutifan in patients with advanced solid tumors (Abstract No: TPS669).

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

About the Merck & Co., Inc., Kenilworth, N.J., U.S.A. and Eisai Strategic Collaboration

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A.

In addition to ongoing clinical studies evaluating the LENVIMA plus KEYTRUDA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.

Eisai's Focus on Cancer

Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where Eisai can aim to become a frontrunner in oncology. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, 'lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.

Newly detected WhisperGate malware being used by previously unknown threat group in cyberattacks against Ukraine

read more

Bitcoin Price Prediction – January 16 Despite the rejection, the Bitcoin price prediction shows that BTC keeps pushing towards the north as the coin has [...]

With January in full flow, let's take a look back the news stories from this week that dominated the worlds of Forex, Fintech and Crypto, in our best of the week segment.

LOUISVILLE, Colo.–(BUSINESS WIRE)–UST, a leading digital transformation solutions company, has partnered with KIOSK Information Systems (KIOSK) to create a highly innovative self-service Retail AI Vision Checkout platform. The edge compute infrastructure provides consumers with autonomous 24 X 7 operational store access. The touchless checkout solution includes both voice and gesture-based UI checkout interaction alternatives, combined […]

The post KIOSK Information Systems and UST to Feature Touchless Vision Checkout Solution at NRF Big Show 2022 appeared first on Fintech News.

2021 was a year of affirmation for the Brazilian crypto market with good news in the national stock market, the promise of a CBDC and Brazilian soccer joining the game.

Blockchain Technology is becoming more popular as it is building trust and boosting the bottom line for all network activities.

The post has appeared first on thenewscrypto.com

Timing of the move has evoked at least some skepticism from security experts about the country's true motives.

A group of U.S.-based banks is launching their own stablecoin, USDF. The stablecoin will be issued by the USDF Consortium, which will allow its members (financial and banking institutions) to issue USDF. The proposed stablecoin will be the first currency of its kind to be minted by FDIC-insured institutions and compliant with the recommendations on […]

The post Ethereum (ETH) and Altcoins Ready to Explode! Bears to lay low Soon? appeared first on Coinpedia - Fintech & Cryptocurreny News Media| Crypto Guide

The crypto market has been in the red since the new year began, with the first week bringing down the most valuable coins by double digits as fear, uncertainty, and doubt (FUD) gripped the global economy amid concerns about inflation, liquidity, and the US Federal Reserve’s next move. After weeks of continuous sell-offs, a well-known …

MEXC Pioneer is partnering with Proximity Labs, a cutting-edge research firm focused on DeFi technology within NEAR ecosystem.  Decentralized finance, or DeFi, has become an essential component of cryptocurrency markets and firmly established itself in the blockchain industry. Today, people are looking for more easy-to-use and reliable DeFi platforms to get involved. Focused on DeFi […]